Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 2, 1997, Pages 184-188

  Culine, Stéphane ^a,c   Théodore, Christine ^a   Bekradda, Mohammed ^a   Farhat, Fadi ^a   Terrier Lacombe, Marie Josée ^a   Droz, Jean Pierre ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

BEP; Chemotherapy; CISCA(II) VB(IV); Germ cell tumors; Poor risk

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINBLASTINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DEATH; DRUG RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; RISK ASSESSMENT; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HUMANS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; RETROPERITONEAL NEOPLASMS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 17144468792     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199704000-00017     Document Type: Article

References (16)

1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-81.
2. Droz JP, Kramar A, Rey A. Prognostic factors in metastatic disease. Semin Oncol 1992;19:181-9.
3. Mead GM. International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: final report of the International Germ Cell Cancer Collaborative Group. Proc Am Soc Clin Oncol 1995;14: 235.
4. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
5. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
6. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 1985;3:326-35.
7. Logothetis CJ, Samuels ML, Selig DE, et al. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors: results with 100 patients. Am J Med 1986;81:219-28.
8. Droz JP, Kramar A, Ghosn M, et al. Prognostic factors in advanced nonseminomatous testicular cancer: a multivariate logistic regression analysis. Cancer 1988;62:564-8.
9. Amato R, Ogden S, Sella A, et al. A strategy for a 95% cure rate in metastatic nonseminomatous germ cell tumors of the testis. Proc Am Assoc Cancer Res 1992;33:221.
10. Einhorn LH, Williams SD. Chemotherapy of disseminated testicular cancer: a random prospective study. Cancer 1980;46: 1339-44.
11. Lederman GS, Garnick MB. Possible benefit of doxorubicin in patients with refractory germ cell cancer. Cancer 1986;58: 2393-8.
12. Harstrick A, Schmoll HJ, Wilke H, et al. High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. Ann Oncol 1990;1:375-6.
13. Stoter G, Akdas A, Fossa SD, et al. High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. Ann Oncol 1992;3:577-8.
14. Samson MK, Rivkin SE, Jones SE, et al. Dose-response and dose-survival advantage for high- versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 1984;53:1029-35.
15. Droz JP, Pico JL, Biron P, et al. No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Proc Am Soc Clin Oncol 1992;11: 197.
16. Miller AB, Hoogstraten B, Staquet B, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.